Ethris, AstraZeneca to develop mRNA therapies for respiratory diseases

Tuesday, August 22, 2017

Ethris, a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, announced a five-year strategic research collaboration with AstraZeneca and its global biologics research and development arm, MedImmune. The collaboration is focused on developing new stabilized non-immunogenic modified RNA therapies for respiratory diseases using Ethris’ proprietary SNIM RNA technology.

[Read More]

AstraZeneca tops out new global R&D center and HQ in Cambridge, UK

Wednesday, April 26, 2017

AstraZeneca marks a key milestone in its successful move to Cambridge, U.K., with the “topping out” of its new, state-of-the-art, strategic R&D center and global corporate headquarters at the heart of the Cambridge Biomedical Campus (CBC). The company, including its biologics research and development arm, MedImmune, already has 2,000 employees actively engaged in the city’s vibrant scientific, academic, clinical and business community. Occupation of the site will begin in stages in 2018.

[Read More]

Milner Therapeutics Institute, Pfizer partner

Friday, January 20, 2017

The Milner Therapeutics Institute has announced Pfizer as a partner to the Milner Therapeutics Consortium. Pfizer has agreed to join the Consortium, which enables the efficient transfer of materials between industry and academia and allocation of funds for partnering opportunities in Cambridge. Dr. Ron Newbold, vice president, External R&D Innovation at Pfizer, will join the Milner Innovation Board alongside representatives from Astex, AstraZeneca, GlaxoSmithKline, Shionogi, MedImmune, University of Cambridge, Babraham Institute and Sanger Institute.

[Read More]

Da Volterra, The Medicines Company join COMBACTE-NET to combat antimicrobial resistance

Friday, November 18, 2016

The Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) project COMBACTE-NET announces that two new pharmaceutical companies, Da Volterra and The Medicines Company, have joined the project as partners. Together with the existing partners the new partners will closely collaborate to further strengthen the public-private partnership aiming to combat the worldwide growing problem of antimicrobial resistance.

[Read More]

Abpro, Essex Bio partner on antibody therapeutics

Tuesday, April 12, 2016

Abpro, an integrated life science company at the forefront of synthetic biology, has partnered with Essex Bio, a China-based biopharmaceutical company. Abpro and Essex will co-develop multiple monoclonal antibodies in immuno-oncology and ophthalmology by leveraging Abpro’s DiversImmune platform. Abpro received a $3.5M equity investment from Essex Bio and an undisclosed amount from affiliates, as part of the agreement.

[Read More]

MedImmune receives FDA Fast Track for influenza treatment

Thursday, March 10, 2016

AstraZeneca’s global biologics R&D arm, MedImmune, has received Fast Track designation from the FDA for its investigational human monoclonal antibody (mAb), MEDI8852, for the treatment of patients hospitalized with type A strain influenza. The FDA’s Fast Track program is designed to expedite the development and review of drugs to treat serious conditions and fill an unmet medical need.

[Read More]

AstraZeneca, MedImmune join chronic kidney disease consortium

Friday, February 12, 2016

AstraZeneca and its global biologics research and development arm MedImmune have entered into a collaboration with the University of Michigan and Eli Lilly to identify new therapeutic targets for the treatment of chronic kidney diseases (CKD). The RPC2 consortium (renal precompetitive consortium) will combine extensive clinical and molecular data collected by Professor Matthias Kretzler at the University of Michigan with the R&D expertise of the pharmaceutical industry.

[Read More]